[go: up one dir, main page]

HN2003000063A - Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. - Google Patents

Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.

Info

Publication number
HN2003000063A
HN2003000063A HN2003000063A HN2003000063A HN2003000063A HN 2003000063 A HN2003000063 A HN 2003000063A HN 2003000063 A HN2003000063 A HN 2003000063A HN 2003000063 A HN2003000063 A HN 2003000063A HN 2003000063 A HN2003000063 A HN 2003000063A
Authority
HN
Honduras
Prior art keywords
combination
tiotropio
diseases
salt
treatment
Prior art date
Application number
HN2003000063A
Other languages
English (en)
Inventor
Simon Bailey
Elisabeth Colette Louise Gautier
Alan John Henderson
Thomas Victor Magee
Anthony Marfat
John Paul Mathias
Dale Gordon Macleod
Sandra Marina Monaghan
Blanda Luzia Christa Stammen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0203196A external-priority patent/GB0203196D0/en
Priority claimed from GB0220984A external-priority patent/GB0220984D0/en
Priority claimed from GB0224454A external-priority patent/GB0224454D0/en
Priority claimed from GB0227140A external-priority patent/GB0227140D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of HN2003000063A publication Critical patent/HN2003000063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION DE UN DERIVADO DE NICOTINAMIDA Y TIOTROPIO O UN DERIVADO DEL MISMO, A COMPOSICIONES QUE LA CONTIENEN Y A LOS USOS DE DICHA COMBINACION
HN2003000063A 2002-02-11 2003-02-10 Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. HN2003000063A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203196A GB0203196D0 (en) 2002-02-11 2002-02-11 Nicotinamide derivatives useful as pde4 inhibitors
GB0220984A GB0220984D0 (en) 2002-09-10 2002-09-10 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases
GB0224454A GB0224454D0 (en) 2002-10-21 2002-10-21 Nicotinamide derivatives and a tiotropium salt in combination for the treatmentof diseases
GB0227140A GB0227140D0 (en) 2002-11-20 2002-11-20 Nicotinamide derivatives and a tiotropium salt in combination for the treatment of diseases

Publications (1)

Publication Number Publication Date
HN2003000063A true HN2003000063A (es) 2004-11-24

Family

ID=27739228

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000063A HN2003000063A (es) 2002-02-11 2003-02-10 Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.

Country Status (10)

Country Link
US (1) US20030220361A1 (es)
AR (1) AR038835A1 (es)
AU (1) AU2003201745A1 (es)
DO (1) DOP2003000585A (es)
HN (1) HN2003000063A (es)
PA (1) PA8566301A1 (es)
PE (1) PE20031037A1 (es)
TW (1) TW200305416A (es)
UY (1) UY27656A1 (es)
WO (1) WO2003068233A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL372756A1 (en) 2002-02-11 2005-08-08 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
US20060251656A1 (en) * 2003-02-11 2006-11-09 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
ES2342468T3 (es) 2003-11-03 2010-07-07 Boehringer Ingelheim International Gmbh Procedimiento para la preparacion de sales de tiotropio.
ES2525684T3 (es) 2004-12-29 2014-12-29 Hadasit Medical Research Services And Development Ltd. Sistemas de cultivo de células madre
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
CN101688178B (zh) 2007-04-18 2013-12-04 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
WO2009035928A1 (en) * 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
SI2297106T1 (sl) * 2008-05-27 2014-09-30 Astrazeneca Ab Fenoksipiridinilamid derivati in njih uporaba pri zdravljenju PDE4 posredovanih bolezenskih stanj
IL305070B2 (en) 2014-12-30 2025-11-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
ES2880346T3 (es) 2014-12-30 2021-11-24 Cell Cure Neurosciences Ltd Evaluación de poblaciones de células epiteliales de pigmento retiniano
EP3328995B1 (en) 2015-07-29 2021-03-31 Hadasit Medical Research Services And Development Large scale production of retinal pigment epithelial cells
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
JP6987769B2 (ja) 2015-10-26 2022-01-05 セル キュア ニューロサイエンシズ リミテッド 網膜色素上皮細胞の調製法
EP3579851A4 (en) 2017-02-08 2020-10-07 Hadasit Medical Research Services And Development LIGHT-RECEPTOR CELLS FOR THE TREATMENT OF RETINAL DISEASES
EP3595687A1 (en) 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
US20210000102A1 (en) 2017-12-29 2021-01-07 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
EP3754014A1 (en) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automated method for preparing retinal pigment epithelium cells
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
JP2024527986A (ja) 2021-07-28 2024-07-26 リネージ セル セラピューティクス インコーポレイテッド 網膜色素上皮細胞の増殖
US20250262248A1 (en) 2022-04-25 2025-08-21 Cell Cure Neurosciences, Ltd. Methods and compositions for treating vision loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EA003528B1 (ru) * 1997-04-04 2003-06-26 Пфайзер Продактс Инк. Производные никотинамида, их применение, фармацевтическая композиция, способ лечения и способ ингибирования изоферментов фдэ4 d

Also Published As

Publication number Publication date
AU2003201745A1 (en) 2003-09-04
US20030220361A1 (en) 2003-11-27
TW200305416A (en) 2003-11-01
UY27656A1 (es) 2003-09-30
WO2003068233A1 (en) 2003-08-21
AR038835A1 (es) 2005-01-26
PA8566301A1 (es) 2003-11-12
PE20031037A1 (es) 2003-12-24
DOP2003000585A (es) 2003-09-30

Similar Documents

Publication Publication Date Title
HN2003000063A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.
NI200300042A (es) Compuestos que modulan la actividad de ppar y metodos para su preparacion.
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
GT200900283A (es) &#34;terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario&#34;.
PA8567801A1 (es) Compuestos que modulan la actividad de ppar
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
PA8592201A1 (es) Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen estos compuestos y sus usos
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
PA8566501A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CU20080223A7 (es) Compuestos de pirrolo-pirimidina y sus usos
GT200300053A (es) Compuestos que modulan la actividad de ppar
PA8680701A1 (es) Derivados de oxindol
GT200300054A (es) Compuestos que modulan la actividad de ppar
CR10304A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR9580A (es) Inhibidores de la actividad akt
NO20071078L (no) Antivirale forbindelser
NO20070866L (no) Antivirale forbindelser.
HN2012001162A (es) Triazolopiridinas
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
PA8595901A1 (es) &#34;n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos